GB Sciences, Inc.
3550 W Teco Avenue
About GB Sciences, Inc.GB Sciences is science-informed and patient-inspired. Here we create medicines, therapies and treatments for a variety of ailments with the extracted compounds of the cannabis plant.
CEO: John Poss
CSO: Andrea Small-Howard
CFO: Ksenia Griswold
FOLLOW GB SCIENCES:
Tweets by GB Sciences
68 articles with GB Sciences, Inc.
GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion; Cannabis Is Medicine; at the State of Cannabis Conference on the Queen Mary
GB Sciences, Inc. (OTCQB: GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research Initiatives.
The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program.
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
Reported revenue of $1,315,284 and gross profit of $734,719
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial.
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
B Sciences, Inc has contracted Adherence Compliance for its Chief Compliance Officer Program and Adherence SCORE App
GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations.
Corporate strategy dedicated to scientific medical research, a viable drug development pipeline and a strong Intellectual Properties Patent Portfolio are cited as the key differentiating factors.
The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures.
GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction.
GB Sciences, Inc. announced that it has appointed John B. Davis as Executive Vice President, General Counsel - effective immediately.
GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").
GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
GB Sciences, Inc. is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities.
GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
GB Sciences, Inc. is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations
GB Sciences enters full commercial operations with its cannabis oil production partners Cura Cannabis Solutions and RWH, a new venture co-founded by Deliciously Dee™
GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More
The new patent application claims the benefit of GB Sciences' provisional patent previously filed on February 1, 2017.
GB Sciences Welcomes Dr. Zoltan Mari, a Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board
Dr. Mari is a renowned expert of clinical research on Parkinson's disease and movement disorders, who is willing to offer his guidance on GB Sciences' Parkinson's disease therapy program.
GB Sciences explains that 100% of the mother plants in their Las Vegas cultivation facility are now products of the GB Sciences tissue propagation initiative.
GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. Carlos Ríos-Bedoya of McLaren Health
GB Sciences inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences' intellectual property portfolio.
GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain
GB Sciences has obtained the exclusive worldwide license to intellectual property covering a time-released cannabinoid formulation from the USE, the UCA, and the CIBERSAM.
Nanotechnology Research Collaboration With Universidad De Sevilla To Create Time-Released Formulation For GB Sciences' THC-Free Chronic Pain Therapy